lucas D schreef:
[quote=Dirk R. Wijnen]
DSM and Crucell Announce PER.C6® Technology Milestone
Leiden, The Netherlands/Parsippany, USA, 11 March 2008 - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that another important milestone has been achieved with the PER.C6® technology platform for the production of monoclonal antibodies and recombinant proteins. Scientists working at PERCIVIA reached a record level titer of 15 g/L at harvest for an antibody product. PERCIVIA is the PER.C6® Development Center joint venture between DSM and Crucell, located in Cambridge, Massachusetts, USA.
Marco Cacciuttolo, CEO of PERCIVIA comments, "This high titer achievement for PER.C6®, the highest reported to date, marks a major event for the biopharmaceutical industry. It demonstrates the power and robustness of the PER.C6® manufacturing platform and it clearly shows that the PER.C6® manufacturing platform will have a major impact to the overall economics of manufacturing biopharmaceuticals. DSM and Crucell recognized the enormous potential of the PER.C6® technology when starting the PERCIVIA joint venture just over 1 year ago. The breakthrough results achieved in a single year reinforce the special properties and abilities of the PER.C6® manufacturing platform. Based on our scientific data today, we are confident that we will be able to drive productivity even further."
Marcel Lubben, VP of Marketing, Sales & Business Development at DSM Biologics added, "We are very enthusiastic about the new 15 g/L milestone for our licensees. The PER.C6® manufacturing platform has tremendous potential for the biotech industry to significantly reduce the cost-of-goods for monoclonal antibodies and recombinant proteins, resulting in more affordable therapeutic treatments for patients."
Martina Molsbergen, VP Business Development at Crucell, added "The PER.C6® platform can reduce the risk of supply limitations and potentially postpone major capital expenditure decision hurdles for drug development companies. The 15 g/L milestone is instrumental in the further market penetration of the PER.C6® technology."
[/quote]
Mooi bericht, dit kon weleens net het zetje zijn wat Crucell nodig had om het sentiment te doen omslaan, en zorgen voor een gestaag hoger sluitende koers.
Het zal me dan nu ook niet verwonderen als Crucell aan het eind van 2008 in het rijtje aandelen staat van de aandelen die het meest in koerswaarde gestegen zijn.
lucas D